A unit of Chinese pharma firm Anke Biotechnology Co. has obtained rights to act as an exclusive franchisee for Verogen Inc., a US firm engaged in next-generation gene sequencing for the legal medicine field.
Wuxi-based AGCU ScienTech Inc. will act as Verogen’s sole sales partner in mainland China, its parent company said in a statement.
The deal includes rights related to Verogen’s new generation sequenator, MiSeq FGX, specially designed for legal medical experts, which is the only technology of its kind to receive approval from the FBI. The parties will also work together on NGS-applicable reagents, data analysis software and technical schemes tailored for complex cases.
As a second-generation gene sequencing technology, NGS has replaced its predecessors in genetics, medicine and agricultural research. The future market potential for the technology in the forensic science field is huge, Anke said in the statement.
Founded in 2000, Anke Biotechnology is engaged in technological research and development in areas like cell engineering, gene engineering and precision medicine. It boasts more than 30 patents for its inventions.
Verogen, an affiliate of gene sequencing behemoth Illumina Inc. established last year, was the world’s first firm devoted to forensic genomics technologies. It has exclusive rights to provide Illumina’s sequencing technology to forensic customers, including for criminal casework.
Source: yicaiglobal.com
